<SEC-DOCUMENT>0001144204-13-055311.txt : 20131016
<SEC-HEADER>0001144204-13-055311.hdr.sgml : 20131016
<ACCEPTANCE-DATETIME>20131015181610
ACCESSION NUMBER:		0001144204-13-055311
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131015
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131016
DATE AS OF CHANGE:		20131015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADHEREX TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		131152849

	BUSINESS ADDRESS:	
		STREET 1:		4620 CREEKSTONE DRIVE
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-484-8484

	MAIL ADDRESS:	
		STREET 1:		4620 CREEKSTONE DRIVE
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v357390_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported)&nbsp;&nbsp;October
15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Adherex Technologies Inc.</b></font></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><i>(Exact Name of Registrant as Specified in Its&nbsp;</i></font><br>
<font style="font: 10pt Times New Roman, Times, Serif"><i>Charter)</i></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Canada</b></font></td>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>001-32295</b></font></td>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>20-0442384</b></font></td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(State or Other Jurisdiction</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>of Incorporation)</i></P></td>
    <TD STYLE="font-size: 10pt">&nbsp;</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Commission</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>File Number)</i></P></td>
    <TD STYLE="font-size: 10pt">&nbsp;</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(IRS Employer</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Identification No.)</i></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PO Box 13628, 68 TW Alexander Drive,
Research Triangle Park, NC 27709</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Address of Principal Executive Offices)
(Zip Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>919-636-4530</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Registrant&rsquo;s Telephone Number,
Including Area Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Not applicable.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Former Name or Former Address, if Changed
Since Last Report)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U><I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Wingdings">&uml;</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Wingdings">&uml;</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Wingdings">&uml;</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Wingdings">&uml;</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>











<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;<B>&nbsp;&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 112px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif; color: #222222"><b>Item&nbsp;8.01</b></font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif; color: #222222"><b>Other Events</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 15, 2013, Adherex Technologies, Inc. (the &ldquo;Company&rdquo;)
issued a press release to announce updated guidance for Sodium Thiosulfate (STS) results. The full text of the press release is
furnished as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 6%; border-bottom: black 1pt solid; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif; color: #222222">Exhibit</font></td>
    <td style="width: 94%; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif; color: #222222">99.1&nbsp;&nbsp;</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif; color: #222222">Press Release issued by Adherex Technologies, Inc. dated October 15, 2013</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Dated:&nbsp;October 15, 2013</font></td>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adherex Technologies Inc.</B></P></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 54%">&nbsp;</td>
    <TD STYLE="width: 3%">&nbsp;</td>
    <TD STYLE="width: 34%">&nbsp;</td>
    <TD STYLE="width: 9%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
    <TD STYLE="border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">/s/ Rostislav Raykov</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</font></td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v357390_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="Description: New Adherex_CMYK copy" STYLE="height: 60px; width: 192px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Adherex Announces Updated Guidance
for Sodium Thiosulfate (STS) Results</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Research Triangle Park, NC, May
23, 2013</B>&nbsp;- Adherex Technologies Inc. (TSX:AHX, OTCQB: ADHXF), <FONT STYLE="color: black">today announced that the results
from Clinical Oncology Group (COG) Study ACCL0431, a phase 3 clinical study evaluating the efficacy of STS compared with observation
in children diagnosed with very rare childhood cancers typically treated with cisplatin therapy are expected to be submitted for
presentation at a scientific meeting in the first half of 2014.&nbsp;Preliminary study data is not available to Adherex for public
disclosure.&nbsp;&quot;Pending the outcome of our analysis of the final study results, Adherex plans to meet with the FDA to agree
on acceptable data package for a New Drug Application for STS,&quot; said Mr. Raykov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Sodium Thiosulfate (STS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">STS is currently FDA-approved as an
antidote for cyanide poisoning. Adherex has licensed from Oregon Health &amp; Science University intellectual property rights for
the use of STS as a chemoprotectant, and are developing STS as a protectant against the hearing loss often caused by platinum-based
anti-cancer agents in children. Preclinical and clinical studies conducted by Oregon Health &amp; Science University and others
have indicated that STS can effectively reduce the incidence of hearing loss caused by platinum-based anti-cancer agents. Adherex
has received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity
in pediatric patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Hearing loss among children receiving
platinum-based chemotherapy is frequent, permanent and often severely disabling. The incidence of hearing loss in these children
depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently
no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner
ear) implants have been shown to provide some benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Except for historical information described
in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties
inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and
patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products
will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will
not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its
ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse
regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in
the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December
31, 2012.&nbsp;Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: black"><I>For
a more detailed discussion of related risk factors, please refer to our public filings available at</I></FONT><I><FONT STYLE="text-underline-style: none; color: #005790">
</FONT></I><I><FONT STYLE="text-underline-style: none; color: Black">www.sec.gov</FONT></I><I><FONT STYLE="color: Black">&nbsp;and&nbsp;<FONT STYLE="text-underline-style: none">www.sedar.com</FONT></FONT><FONT STYLE="color: black">.</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>For further information, please
contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Rosty Raykov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Adherex Technologies Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">T: (919) 636-5144</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #002C40">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"``\`,`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T3QS+Y?AU
M@#R\BC%>;5W7Q"E*VEK%GAW)Q]*XJVA-Q=1Q#JYQ7JX16I7.&L_?9%TY]*]<
MT.7SM$LY/[T0->1D8)'H<5Z;X-F\WPY$3_`Q7\JG&J\$QX=^\;,]S#:Q[YY4
MC7U8XJ*WU.RNGVP7,4C>BM7F?B34Y=2UB8NQ\J-MJ+G@"LR(R+(K0EPZG(*]
M:SC@KQNWJ4\0[Z+0O^(O^1CU#_KL:G\)?\C';?4UEW$\ES<233'=(YRQ]36I
MX2_Y&.V^IKKDK4FO(QO>5RIK/_(:O/\`KJ:U?`O_`",?_;%OZ5E:S_R&KS_K
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M]U%ISVD<KA9&RYSR?:K>"?1D_6?(]:CFCE!,;JP!P<'-/KE?`'_(&ER2?WIZ
MUU5<E2'))Q-X2YHW"BBBH+"BBB@#@/B!/OU"VAS]Q"V/K6)X>C$NOV:D`CS.
M0>_%7O&LPE\1N!T1`M5_"TD,.O0R7$BQH@)W-TKUX+EH?(\^3O._F9UXGEWL
MZ>CD?K7;^`I]VE7,.?N.3^=<=K!1M9O#$X>,RDJPZ$5T7@"<+<7L/]]`P_"E
MB%S4;CI:31RMR2;J8GKO/\ZZ#P(JMKK[@#^Z/6N?N/\`CYE_WS_.NB\!_P#(
M=?\`ZY&KK?PGZ$T_B1E>(($M]>O8XP`@D.`.U3^$O^1CMOJ:9XG_`.1CO?\`
MKH:?X2_Y&.V^IH?\'Y!]KYE36?\`D-7G_74U?\'(K^(8PZA@$8X(]JH:S_R&
MKS_KJ:T/!G_(Q1_]<V_E1/\`A/T"/Q(R;Y0E_<*HP!(>*VO`_P#R,!_ZX-6-
MJ'_(1N?^NAK9\$?\C`?^N#45?X3]`I_$C"N26NIB3DESS^-;/A&]MK#57ENY
M%1#&0"WK6-<?\?,O^^?YU8TS2KC6+DP6NS>%W?.<#%7-)P:>Q,;W5B"Z*->3
M-']PN2OTK<\)N0FIKGY6MR2*8?!U^"09[($=O.K4T70[G2X;^6>2W=6@('EO
MN-95*D'"R92C)'&]S]:<B%S@4WN?K5B$?NZC&5W1I<T=S"K/DC=&CIVL7FEV
MQ@M9`J$[CQWJ]!XOU.*3<[I(O<,*S])@2YU>TAE&8Y)`K#U%3^(+6*SUF:&!
M=L8Z#TKY]U)R]]LP4ZJASJ74T)_&NH-*3`L2QGHK+DC\:N:)XMNKK4XX+[RA
M')P"JXP>U<M;V\ES(4B&6"EL>M1JQ1PRG#*<CV-)5))WN..)JIJ39W/B;Q'-
MI=Q%!9[#(1N?<,X':LNP\4:Q?WT5M'Y&YSC.SI[USUU<R7ER\\[;G;J:Z[P5
MIFR)[^1?F?Y8\]AW-6I2G/1F\*M2O6M%M+]#D?$,OG>(+UQT\P@?2LX`GH"3
M["I+AVFN))"K?.<]#71^`X"^M22,O"QD<CUKZ64O9T[]C5+FEZG,=.H(^M;_
M`(*E\O7PI/#Q,OXU%XM@,/B*XPIP^&X'K5?P[(8?$%DQ#`&0`\'I2D^>DWW0
MU[LBE=J4O)E/4.?YUT'@,@:Z^3_RR-4/$VG/IVMS[D(BD8O&>Q!K,@EEBE!M
MW99#QE.M#7M*=EU$O=?H7_$4BR^(;YE(*^:0".]3>$O^1CMOJ:R75T=E=6#`
M\@BM?PE_R,=MP>IHFK4VO($[RN4]9_Y#5Y_UU-:'@S_D8H_^N;?RK/UD'^VK
MSY6_UI[&M'P8#_PD4?!_U;=1[4I_PGZ#C\2,G4/^0C<_]=#6SX(_Y&`_]<&K
M&U`'^T;CY6_UA[&MOP*#_P`)'R#_`*ENH^E%7^$_0*?Q(P+GBZFSQ\Y_G70^
M!/\`D-R?]<C3?%GA^>QOY+J&-GMI3NRH^X?2L&WNY[*7S+:9X9,8W*<'%#M5
MI^[U!+DEKT'WY/\`:-Q\S?ZP]ZV?">XKJ1Y(%N>]8"AYI/E#.['L,DFNZT/0
MY=*\.WLUR-L\\9)7^Z,<4JTE&%F*$6S@^Y^M6(?]75?G)X/7TJQ#_JZY,T_A
M+U.;$?"B:-WBD5XBRNIRI7J#3I9)KB0R3&1W/5F!S5_PV,Z_:Y&1NK<\0>(;
MS3=5:WMU@\L*#\R9->(H^[=LSA33I\\G97,CPLI_MZ#*MCGJ#4?B.P73]9EC
MC(V/\Z@=L]JUM)\57<]^%NO(6$*68JF#7/:C>-?W\UP^?G8D#T%-\O)9%3=-
M44HN[N,LK8WE]#;@@&1PN37JEM`EK;1PQC"(NT"O)D=HI%="0RG((KU'2+]=
M2TR&X!&2,,/0]ZTH-:G3ESC>2ZDWV.V_YX1_]\BGQP11$F.-5)ZX&*DHKJNS
MT[(B>WAE;=)$C-ZD9I!:0*P*PQ@CH0HJ:BB["R(+JRM[V/9=0I*OHPS5:UT'
M3;.0/!9Q*XY#8Y%:%%-2DE9,3BF[M%1M,LG8LUK$2>22M.BT^TAD#Q6\:..A
M"\U9HHYGW#DCV(6M(&8EH8R3U)44J6T,;;DB13ZA<5+12NQV1";2W)),,9)_
MV12I;PQ-NCB16Z9`Q4M%%V%D(RA@0P!![&J$F@Z7*Y:2Q@9CW*UH44*36S!I
M/<J6VE6-FVZVM8HSZJM6F4.I5@"#P0:6BAMO5@DEL4_[)L?^?2'_`+YKB?%N
MF_8M2$D482"5>,#@'O7H507EG!?V[0W,8=#V/:HJ)SC9LYZ^'52%EHSR_3[L
MV&H0W(7=Y;9V^M2ZOJ/]JZB]SY>P$`!<YJ;7=.ATZ],5ONVY_B.:BTBRBOKU
M8IMVTD?=.*XM?A/&]Y?N[]2B&(S@XSP:GL;1[Z]BMX^LC8SZ"NNN/"NG"8@+
M*`.,!ZN:+H-G879GA#EP,`LV<5:I.]F;PPLG-)LXS6=,?2=0>!LE.J-ZBMGP
M5J7DW;V4A^23YDSV-='KFDVVI0H;A6RAX*G!K*M_#=E;W$<L1F#HV5._H:OD
,<)W1K[&5&MS1V/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
